Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024
Omeros (NASDAQ: OMER) has announced that it will release its financial results for the second quarter ended June 30, 2024, on Wednesday, August 7, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on the same day to discuss the financial results, recent developments, and highlights.
Investors can access the live webcast through Omeros' website at https://investor.omeros.com/upcoming-events. To join the conference call via phone, participants must register online to receive a unique PIN. A replay of the call will be available at https://investor.omeros.com/archived-events.
Omeros (NASDAQ: OMER) ha annunciato che rilascerà i suoi risultati finanziari per il secondo trimestre chiuso il 30 giugno 2024, mercoledì 7 agosto 2024, dopo la chiusura del mercato. L'azienda ospiterà una conference call e webcast alle 16:30 ora orientale (13:30 ora del Pacifico) lo stesso giorno per discutere dei risultati finanziari, degli sviluppi recenti e delle novità.
Gli investitori possono accedere al webcast dal vivo attraverso il sito web di Omeros all'indirizzo https://investor.omeros.com/upcoming-events. Per partecipare alla conference call via telefono, i partecipanti devono registrarsi online per ricevere un PIN unico. Una registrazione della chiamata sarà disponibile all'indirizzo https://investor.omeros.com/archived-events.
Omeros (NASDAQ: OMER) ha anunciado que publicará sus resultados financieros del segundo trimestre que terminó el 30 de junio de 2024, el miércoles 7 de agosto de 2024, después del cierre del mercado. La compañía organizará una llamada de conferencia y webcast a las 4:30 p.m. hora del Este (1:30 p.m. hora del Pacífico) el mismo día para discutir los resultados financieros, desarrollos recientes y aspectos destacados.
Los inversionistas pueden acceder al webcast en vivo a través del sitio web de Omeros en https://investor.omeros.com/upcoming-events. Para unirse a la llamada de conferencia por teléfono, los participantes deben registrarse en línea para recibir un PIN único. Una repetición de la llamada estará disponible en https://investor.omeros.com/archived-events.
오메로스 (NASDAQ: OMER)는 2024년 6월 30일로 종료되는 2분기 재무 결과를 2024년 8월 7일 수요일에 시장 종료 후 발표할 것이라고 발표했습니다. 회사는 같은 날 오후 4시 30분(태평양 표준시 기준 오전 1시 30분)에 컨퍼런스 콜 및 웹캐스트를 개최하여 재무 결과, 최근 개발 사항 및 하이라이트에 대해 논의할 것입니다.
투자자는 오메로스의 웹사이트 https://investor.omeros.com/upcoming-events를 통해 라이브 웹캐스트에 접속할 수 있습니다. 전화로 컨퍼런스 콜에 참여하려면, 참가자는 온라인으로 등록하여 고유 PIN을 받아야 합니다. 통화의 재생은 https://investor.omeros.com/archived-events에서 확인할 수 있습니다.
Omeros (NASDAQ: OMER) a annoncé qu'il publiera ses résultats financiers pour le deuxième trimestre clos le 30 juin 2024, le mercredi 7 août 2024, après la clôture des marchés. L'entreprise organisera une conférence téléphonique et un webinaire le même jour à 16h30, heure de l'Est (13h30, heure du Pacifique), pour discuter des résultats financiers, des développements récents et des points saillants.
Les investisseurs peuvent accéder au webinaire en direct via le site web d'Omeros à l'adresse https://investor.omeros.com/upcoming-events. Pour participer à la conférence téléphonique par téléphone, les participants doivent s'inscrire en ligne pour recevoir un code PIN unique. Un enregistrement de l'appel sera disponible à l'adresse https://investor.omeros.com/archived-events.
Omeros (NASDAQ: OMER) hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal, das am 30. Juni 2024 endet, am Mittwoch, den 7. August 2024, nach Börsenschluss veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time (13:30 Uhr Pacific Time) eine Konferenzschaltung und ein Webcast abhalten, um die Finanzergebnisse, aktuelle Entwicklungen und Highlights zu besprechen.
Investoren können auf den Live-Webcast über die Website von Omeros unter https://investor.omeros.com/upcoming-events zugreifen. Um an der Telefonkonferenz teilzunehmen, müssen sich die Teilnehmer online registrieren, um eine eindeutige PIN zu erhalten. Eine Wiederholung des Anrufs wird unter https://investor.omeros.com/archived-events verfügbar sein.
- None.
- None.
Conference Call Details
For online access to the live webcast of the conference call, go to Omeros’ website at https://investor.omeros.com/upcoming-events.
To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you will have two options: (1) Dial in to the conference line provided at the registration site using the PIN provided to you, or (2) choose the “Call Me” option, which will instantly dial the phone number you provide. Should you lose your PIN or registration confirmation email, simply re-register to receive a new PIN.
A replay of the call will be made accessible online at https://investor.omeros.com/archived-events.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently in a Phase 1 multi-ascending-dose clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing toward Phase 3 clinical trials for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros’ lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder and, in addition, is being developed as a therapeutic for other addictions as well as for a major complication of treatment for movement disorders. Omeros also is advancing a broad portfolio of novel immuno-oncology programs comprised of two cellular and three molecular platforms. For more information about Omeros and its programs, visit www.omeros.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240805500419/en/
Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations
IR@omeros.com
Source: Omeros Corporation
FAQ
When will Omeros (OMER) release its Q2 2024 financial results?
What time is Omeros 's (OMER) Q2 2024 earnings call scheduled for?
How can investors access Omeros 's (OMER) Q2 2024 earnings call?
Will there be a replay available for Omeros 's (OMER) Q2 2024 earnings call?
